Get the Stockscreener App
17.97
1.70%
-0.31
After Hours:
17.85
-0.12
-0.67%
Edgewise Therapeutics Inc stock is traded at $17.97, with a volume of 1.11M.
It is down -1.70% in the last 24 hours and up +14.82% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$18.28
Open:
$18.28
24h Volume:
1.11M
Relative Volume:
1.30
Market Cap:
$1.89B
Revenue:
-
Net Income/Loss:
$-150.70M
P/E Ratio:
-11.59
EPS:
-1.55
Net Cash Flow:
$-125.67M
1W Performance:
+12.10%
1M Performance:
+14.82%
6M Performance:
+6.27%
1Y Performance:
-47.15%
1-Day Range:
$17.64
$18.61
1-Week Range:
$15.66
$18.80
52-Week Range:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
17.97 | 1.93B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Truist Securities reiterates Buy rating on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Edgewise Therapeutics prepares for pivotal research in cardiovascular medicine - Traders Union
Published on: 2025-11-03 07:00:03 - newser.com
Edgewise Therapeutics (Nasdaq: EWTX) reports 170,750 inducement options to 7 hires - Stock Titan
Real time alert setup for Edgewise Therapeutics Inc. performanceJuly 2025 Outlook & Weekly Setup with High ROI Potential - newser.com
What hedge fund activity signals for Edgewise Therapeutics Inc. stockEntry Point & Scalable Portfolio Growth Ideas - newser.com
Risk vs reward if holding onto Edgewise Therapeutics Inc.July 2025 Market Mood & Safe Entry Trade Reports - newser.com
Strategies to average down on Edgewise Therapeutics Inc.Weekly Stock Report & Daily Profit Maximizing Tips - newser.com
Can Edgewise Therapeutics Inc. stock beat analyst upgradesJuly 2025 Trade Ideas & Daily Technical Forecast Reports - newser.com
Detecting price anomalies in Edgewise Therapeutics Inc. with AIWeekly Investment Report & Precise Swing Trade Entry Alerts - newser.com
Real time breakdown of Edgewise Therapeutics Inc. stock performanceWeekly Gains Report & Consistent Profit Alerts - newser.com
What recovery options are there for Edgewise Therapeutics Inc.2025 Top Decliners & AI Powered Trade Plan Recommendations - newser.com
Chart overlay techniques for tracking Edgewise Therapeutics Inc.Take Profit & Safe Capital Growth Trade Ideas - newser.com
What valuation multiples suggest for Edgewise Therapeutics Inc. stockWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Edgewise Therapeutics Inc. stock prediction for this weekJuly 2025 Market Mood & Stepwise Swing Trade Plans - newser.com
Edgewise Therapeutics soars 62% after InvestingPro’s April fair value alert By Investing.com - Investing.com Australia
Analyzing Edgewise Therapeutics Inc. with risk reward ratio chartsWeekly Risk Report & Reliable Intraday Trade Alerts - newser.com
Is Edgewise Therapeutics Inc. stock supported by innovation pipelineGap Down & Expert Approved Trade Ideas - newser.com
Does Edgewise Therapeutics Inc. show high probability of rebound2025 Bull vs Bear & Weekly Breakout Watchlists - newser.com
Multi asset correlation models including Edgewise Therapeutics Inc.Forecast Cut & AI Based Buy and Sell Signals - newser.com
Moody Aldrich Partners LLC Lowers Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Risk adjusted return profile for Edgewise Therapeutics Inc. analyzedJuly 2025 PreEarnings & Intraday High Probability Alerts - newser.com
What analysts say about Edgewise Therapeutics Inc stockEconomic Indicators Overview & Superior Wealth Growth - earlytimes.in
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 9.5%Here's What Happened - MarketBeat
Edgewise Therapeutics (EWTX) Expected to Announce Earnings on Thursday - MarketBeat
Published on: 2025-10-31 05:56:48 - newser.com
Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - ADVFN
How to build a custom watchlist for Edgewise Therapeutics Inc.Quarterly Market Review & Long Hold Capital Preservation Plans - newser.com
Edgewise Therapeutics, Inc. (EWTX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Edgewise Therapeutics set to unveil Q3 2025 results pre-market Nov 6 - Traders Union
Edgewise Therapeutics Advances with Phase 1 Study of EDG-15400 - MSN
Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study - MSN
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):